One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2019-129393
Copy DOI Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 3 |
Affiliation: Fred Hutch Cancer Center, Jena University Hospital, Royal Adelaide Hospital, South Australia Pathology, University of Turin, South Australian Health and Medical Research Institute, Seoul St. Mary's Hospital, Novartis (France), Tris Pharma (United States), Novartis (India), University of BordeauxAnalyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
